Cannasouth Limited (NZX:CBD), New Zealand’s first and largest listed medicinal cannabis company, is pleased to provide this trading update as the Group commences sales of its own-manufactured CBD oral solutions and dried cannabis flower products.
Group Revenues:
Oct-23 $26,000
Nov-23 $201,000
Dec-23 $243,000
Commercial sales of these products commenced in November 2023 following a lengthy verified process by the Medicinal Cannabis Agency. We are confident with the launch of our new products and expect ongoing revenue growth as clinics and prescribers obtain access to our product range either direct, or via wholesalers.
-ENDS-
For further information visit www.cannasouth.co.nz or contact:
Mark Lucas CEO / Executive Director
Email: [email protected]
Mobile: 021 484 649
Colin Foster
CFO / Company Secretary
Email: [email protected]
Mobile: 027 577 1498
The value of Infratil's holding has grown tenfold since acquisition.
The S&P/NZX 50 Index closed at 13,072.93, up 5.1 points or 0.039%.
Experts are picking a surge in mergers and acquisitions activity for 2025.
To join your company account for BusinessDesk and enjoy full access, enter your email and we’ll send you details